New diagnostic test 'can assess lung cancer'

A new lung cancer test developed from a similar test in breast cancer patients by scientists in the US can identify those most likely to benefit from post surgery treatment.

Patients with non-small cell lung cancer (NSCLC) have between a 30 and 50 per cent relapse rate following surgery to remove the tumour in the lungs.

By analysing the gene signature of people suffering with the illness, doctors believe they can assess the prognosis and development of the disease just like they are able to do in breast cancer incidences.

"To the best of our knowledge, our study is the first to show a high consistency of the gene signature on both breast cancer and NSCLC," said Dung Tsa Chen, author of the research.

He added that the malignancy-risk gene signature may then be used to identify those people who could be given adjuvant chemotherapy to improve their survival chances.

According to Macmillan, around four out of five lung cancer cases are NSCLC, with surgery the preferred treatment option.

Comment on this page »


Latest news

AXA PPP healthcare win at UK Customer Experience awards 2015

David Mobbs retires as CEO of Nuffield Health

King's victorious at World Transplant Games

New diagnostic test 'can assess lung cancer'
Connect with us on:

This site compiles with the HONcode standard for trustworthy health information